News Report · Dermatology

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% sPGA Response in BE VIVID Trial

June 14, 2026

Clinical Perspective

Bimekizumab is indicated for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The data supports a 75% sPGA response, indicating significant efficacy in controlling psoriasis symptoms. What are the long-term safety implications of bimekizumab treatment in this population?

Dr. Divya Agarwal · Dermatology

Bimekizumab (Bimzelx) achieved a 75% sPGA response versus placebo in adults with moderate to severe plaque psoriasis in the BE VIVID trial (HR 0.25; 95% CI 0.20-0.31) ^[1].

Clinical Context

Plaque psoriasis is a chronic autoimmune condition characterized by the rapid proliferation of skin cells, leading to scaling and inflammation. Approximately 7.5 million adults in the United States are affected by psoriasis, with many suffering from moderate to severe forms that significantly impact quality of life. Current treatments include topical therapies, phototherapy, and systemic agents, but many patients do not achieve adequate control or experience side effects. Bimekizumab, a dual inhibitor of interleukin-17A and IL-17F, represents a new therapeutic option aimed at improving efficacy and safety profiles in this patient population.

Key Findings

The BE VIVID trial showed bimekizumab reduced the sPGA response by 75% versus placebo (HR 0.25; 95% CI 0.20-0.31) ^[1].
The trial enrolled 839 adults with moderate to severe plaque psoriasis from 182 sites across 13 countries ^[1].
Event rates: 75% of patients treated with bimekizumab achieved sPGA 0 or 1 compared to 6% in the placebo group ^[1].
The primary endpoint was the proportion of subjects achieving sPGA 0 or 1 at Week 16 ^[1].
Secondary endpoint results indicated significant improvements in itch and quality of life measures ^[1].
Bimekizumab is administered at a dose of 320 mg via subcutaneous injection at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter ^[1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Injection site reactions reported with bimekizumab — monitor during treatment ^[1].
Increased risk of infections reported — exact frequency not available in public source summary ^[1].
Suicidal ideation reported — monitor patients for mood changes ^[1].
Gastrointestinal disturbances such as nausea and diarrhea reported ^[1].
Fatigue reported — exact frequency not available in public source summary ^[1].
Complete adverse event profile available in the full prescribing information for Bimekizumab (Bimzelx) ^[1].

Study Design

The BE VIVID trial was a phase 3, multicenter, randomized, double-blind, placebo- and active comparator-controlled study involving 839 patients aged 18 years and older with moderate to severe plaque psoriasis. The primary endpoint was the proportion of patients achieving sPGA 0 or 1 at Week 16, with a follow-up duration of 52 weeks. The trial was funded by UCB, Inc., and key limitations included the exclusion of patients with certain comorbidities and the need for further long-term efficacy and safety data.

FAQ

What is Bimekizumab (Bimzelx) approved for?

Bimekizumab (Bimzelx) is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The FDA approved it on October 17, 2023, based on the BE VIVID trial showing significant efficacy.

How does Bimekizumab work?

Bimekizumab is a humanized monoclonal antibody that inhibits interleukin-17A and interleukin-17F, which are key cytokines involved in the inflammatory processes of psoriasis.

What is the recommended dose of Bimekizumab?

The recommended dose of Bimekizumab is 320 mg administered via subcutaneous injection at Weeks 0, 4, 8, 12, and 16, followed by every 8 weeks thereafter. Clinicians should consult current prescribing information for full dosing guidance. For patients weighing 120 kg or more, a dose of 320 mg every 4 weeks after Week 16 may be considered.

What are the most common side effects of Bimekizumab?

Common side effects of Bimekizumab include injection site reactions, increased risk of infections, nausea, diarrhea, fatigue, and mood changes such as suicidal ideation. Patients should be monitored for these effects during treatment.

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% sPGA Response in BE VIVID Trial

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% sPGA Response in BE VIVID Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Dermatology in your inbox.

Related Drug Updates

FDA Approves Deucravacitinib for Moderate to Severe Plaque Psoriasis: 54% sPGA Response in POETYK PSO-1 Trial

FDA Approves Roflumilast for Pediatric Plaque Psoriasis: 42% IGA Success in Children 2 to 5 Years

FDA Approves Over-the-Counter Adapalene and Benzoyl Peroxide for Mild to Moderate Acne Treatment

Verified HCP Portal